Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-DADA
2024-517761-17-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University of Cologne. Primary endpoint: Response (≥VGPR) after 8 cycles of DVCd. Planned start Oct 2024; status: authorised.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517761-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517761-17-00.